Codexis Inc (CDXS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $127.13M
Last updated: Nov 17, 2026 at 11:04 AM ET
Codexis Inc (CDXS) Earnings: Report Dates and Results
Codexis (CDXS) is expected to report earnings on Mar 9, 2027. In the quarter ended Sep 30, 2026, Codexis reported EPS of -$0.08, above the -$0.09 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CDXS has an expected report date of Mar 9, 2027.
CDXS Earnings Call
The latest CDXS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CDXS beat 20, missed 19 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $19.26M, up 124.0% from $8.60M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.08 | -$0.09 | -$0.11 - -$0.08 | +11.11% | Beat | N/A | 2 | 1 up, 0 down | Nov 12, 2026 | $19.26M |
| Jun 30, 2026 | -$0.13 | -$0.17 | N/A | +23.53% | Beat | N/A | 2 | 0 up, 1 down | Aug 11, 2026 | $14.91M |
| Mar 31, 2026 | -$0.10 | -$0.10 | -$0.13 - -$0.08 | 0.00% | In line | N/A | 2 | 0 up, 1 down | May 7, 2026 | $15.25M |
| Dec 31, 2025 | $0.14 | -$0.04 | -$0.06 - -$0.01 | +485.44% | Beat | N/A | 2 | 1 up, 0 down | Mar 11, 2026 | $38.91M |
| Sep 30, 2025 | -$0.22 | -$0.13 | -$0.15 - -$0.10 | -69.23% | Miss | N/A | 3 | 1 up, 1 down | Nov 6, 2025 | $8.60M |
| Jun 30, 2025 | -$0.16 | -$0.15 | -$0.18 - -$0.10 | -6.67% | Miss | N/A | 3 | 1 up, 2 down | Aug 13, 2025 | $15.33M |
| Mar 31, 2025 | -$0.25 | -$0.21 | -$0.24 - -$0.16 | -19.05% | Miss | N/A | 4 | 0 up, 1 down | May 14, 2025 | $7.54M |
| Dec 31, 2024 | -$0.13 | -$0.04 | -$0.06 - $0.05 | -225.00% | Miss | N/A | 6 | 2 up, 2 down | Feb 27, 2025 | $21.46M |
| Sep 30, 2024 | -$0.29 | -$0.21 | -$0.26 - -$0.19 | -38.10% | Miss | N/A | 8 | 1 up, 0 down | Oct 31, 2024 | $12.83M |
| Jun 30, 2024 | -$0.32 | -$0.24 | N/A | -33.33% | Miss | N/A | 7 | 0 up, 0 down | Aug 8, 2024 | $7.98M |
| Mar 31, 2024 | -$0.16 | -$0.14 | -$0.22 - -$0.14 | -14.29% | Miss | N/A | 7 | 0 up, 1 down | May 2, 2024 | $17.07M |
| Dec 31, 2023 | -$0.10 | -$0.12 | -$0.31 - -$0.03 | +16.67% | Beat | N/A | 7 | 0 up, 0 down | Feb 28, 2024 | $26.56M |
| Sep 30, 2023 | -$0.31 | -$0.26 | N/A | -19.23% | Miss | N/A | 7 | 0 up, 0 down | Nov 2, 2023 | $9.28M |
| Jun 30, 2023 | -$0.17 | -$0.14 | -$0.30 - -$0.11 | -21.43% | Miss | N/A | 8 | 4 up, 0 down | Aug 3, 2023 | $21.32M |
| Mar 31, 2023 | -$0.34 | -$0.25 | N/A | -36.00% | Miss | N/A | 8 | 0 up, 0 down | May 4, 2023 | $12.98M |
| Dec 31, 2022 | -$0.14 | -$0.23 | -$0.28 - -$0.18 | +39.13% | Beat | N/A | 8 | 0 up, 0 down | Feb 23, 2023 | $30.37M |
| Sep 30, 2022 | -$0.15 | -$0.16 | -$0.22 - -$0.12 | +6.25% | Beat | -600.0% | 8 | 0 up, 0 down | Nov 3, 2022 | $34.47M |
| Jun 30, 2022 | -$0.04 | -$0.12 | -$0.18 - -$0.08 | +66.67% | Beat | N/A | 8 | 1 up, 1 down | Aug 4, 2022 | $38.41M |
| Mar 31, 2022 | -$0.13 | -$0.15 | -$0.20 - -$0.15 | +13.33% | Beat | N/A | 8 | 0 up, 0 down | May 5, 2022 | $35.34M |
| Dec 31, 2021 | -$0.16 | -$0.22 | -$0.26 - -$0.17 | +27.27% | Beat | N/A | 7 | N/A | Feb 24, 2022 | $24.50M |
| Sep 30, 2021 | $0.03 | -$0.05 | N/A | +160.00% | Beat | N/A | 8 | 4 up, 0 down | Nov 4, 2021 | $36.77M |
| Jun 30, 2021 | -$0.01 | -$0.12 | N/A | +91.67% | Beat | N/A | 8 | N/A | Aug 5, 2021 | $25.45M |
| Mar 31, 2021 | -$0.09 | -$0.18 | -$0.26 - -$0.11 | +50.00% | Beat | N/A | 8 | N/A | May 6, 2021 | $18.03M |
| Dec 31, 2020 | -$0.06 | -$0.12 | -$0.15 - -$0.08 | +50.00% | Beat | -400.0% | 6 | N/A | Feb 25, 2021 | $36.00M |
| Sep 30, 2020 | -$0.06 | -$0.05 | N/A | -20.00% | Miss | -250.0% | 6 | N/A | Nov 5, 2020 | $18.39M |
| Jun 30, 2020 | -$0.07 | -$0.13 | -$0.28 - -$0.13 | +46.15% | Beat | N/A | 6 | N/A | Aug 6, 2020 | N/A |
| Mar 31, 2020 | -$0.13 | -$0.15 | -$0.19 - -$0.09 | +13.33% | Beat | N/A | 5 | N/A | May 7, 2020 | $14.67M |
| Dec 31, 2019 | $0.02 | $0.05 | N/A | -60.00% | Miss | N/A | 4 | N/A | Feb 27, 2020 | $18.65M |
| Sep 30, 2019 | $0.04 | -$0.05 | N/A | +180.00% | Beat | N/A | 4 | N/A | Nov 5, 2019 | $21.91M |
| Jun 30, 2019 | -$0.08 | -$0.07 | -$0.14 - -$0.04 | -14.29% | Miss | N/A | 3 | N/A | Aug 6, 2019 | $12.32M |
| Mar 31, 2019 | -$0.05 | -$0.08 | -$0.13 - -$0.04 | +37.50% | Beat | N/A | 5 | N/A | May 6, 2019 | $15.58M |
| Dec 31, 2018 | -$0.01 | -$0.03 | -$0.05 - $0.00 | +66.67% | Beat | -150.0% | 5 | N/A | Feb 26, 2019 | $16.07M |
| Sep 30, 2018 | -$0.04 | -$0.03 | N/A | -33.33% | Miss | N/A | 5 | N/A | Nov 8, 2018 | $16.95M |
| Jun 30, 2018 | -$0.02 | -$0.08 | N/A | +75.00% | Beat | N/A | 5 | N/A | Aug 8, 2018 | $13.54M |
| Mar 31, 2018 | -$0.05 | -$0.08 | N/A | +37.50% | Beat | N/A | 3 | N/A | May 10, 2018 | $14.04M |
| Dec 31, 2017 | $0.02 | $0.05 | $0.03 - $0.08 | -60.00% | Miss | N/A | 3 | N/A | Mar 8, 2018 | $21.72M |
| Sep 30, 2017 | -$0.21 | -$0.15 | N/A | -40.00% | Miss | -800.0% | 3 | N/A | Nov 9, 2017 | $9.98M |
| Jun 30, 2017 | -$0.13 | -$0.12 | -$0.14 - -$0.12 | -8.33% | Miss | -360.0% | 3 | N/A | Aug 9, 2017 | $10.35M |
| Mar 31, 2017 | -$0.18 | -$0.14 | N/A | -28.57% | Miss | N/A | N/A | N/A | May 9, 2017 | $7.97M |
| Dec 31, 2016 | -$0.13 | -$0.11 | N/A | -18.18% | Miss | N/A | N/A | N/A | Mar 9, 2017 | $9.97M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.49, after -$0.90 the year before. It was -$0.22 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.49 | N/A |
| Dec 31, 2024 | -$0.90 | N/A |
| Dec 31, 2023 | -$0.92 | N/A |
| Dec 31, 2022 | -$0.46 | N/A |
| Dec 31, 2021 | -$0.23 | N/A |
| Dec 31, 2020 | -$0.32 | N/A |
| Dec 31, 2019 | -$0.07 | N/A |
| Dec 31, 2018 | -$0.12 | N/A |
| Dec 31, 2017 | -$0.50 | N/A |
| Dec 31, 2016 | -$0.22 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,300 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,260 | 12 | |
| 2026Q2 | Jun 30, 2026 | 5,090 | 11 | |
| 2026Q1 | Mar 31, 2026 | 4,064 | 9 | |
| 2025Q4 | Dec 31, 2025 | 5,323 | 9 | |
| 2025Q3 | Sep 30, 2025 | 3,101 | 8 | |
| 2025Q2 | Jun 30, 2025 | 4,516 | 9 | |
| 2025Q1 | Mar 31, 2025 | 4,971 | 11 | |
| 2024Q4 | Dec 31, 2024 | 7,319 | 12 |
2026Q3 Earnings Call
Opening remarks
Georgia Erbez Chief Financial Officer and Chief Business Officer Thank you, operator. With me today are Alison Moore, President and Chief Executive Officer; Stefan Lutz, Chief Scientific Officer; and Britton Jimenez, Senior Vice President, Sales and Marketing. During this call, management will make a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our guidance for 2026 revenue, anticipated milestones and product launches, facility expansions, technical milestones and public announcements related thereto, as well as our strategies and prospects for revenue growth and successful execution of current and future programs and partnerships. To the extent these statements contained in the call are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the beliefs and expectations of management as of the statement date, November 12, 2026. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis' control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexis' filings with the Securities and Exchange Commission. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. And now I'll turn the call over to Alison.
Alison Moore President and Chief Executive Officer Thank you, Georgia, and thanks, everyone, for joining the call. Codexis generates manufacturing solutions using highly engineered enzymes. The use of biocatalysis in the pharmaceutical industry has dramatically advanced the production of complex small molecule therapeutics, and we are now focused on delivering a significantly improved enzymatic production system to manufacture oligonucleotide medicines. As we enter the final quarter of 2026, I am very proud of our accomplishments so far. Today, we reported solid third quarter results with revenues of $19.3 million, our fourth consecutive quarterly on-target performance. Early in the quarter, we completed an equity offering in which we raised $25 million of net proceeds. In addition, this week, we announced we entered into a $60 million term loan agreement, of which $42.5 million was used in an initial drawdown to replace an existing loan. This combination of strong operating performance, bolstering our cash balance and deferring our debt repayment has strengthened our financial position as we complete the year. Georgia will give us more details on our financial achievements later in the call. 2026 has been a year of recognition for the developers of RNAi medicines, recognition of the huge therapeutic opportunity in large-population indications and also recognition that traditional manufacturing methods are insufficient to support the commercial aspirations of these important new medicines. Exploration of enzymatic approaches is building significantly, and Codexis' ECO Synthesis platform is in the lead in defining alternative approaches.
Frequently Asked Questions About CDXS
When is Codexis's next earnings date?
Codexis's next earnings report is expected for Mar 9, 2027.
Did CDXS beat earnings estimates last quarter?
Yes. Codexis reported EPS of -$0.08 for the quarter ended Sep 30, 2026, above the -$0.09 estimate, a 11.11% surprise.
What EPS do analysts expect from CDXS next quarter?
The consensus EPS estimate for Codexis for the quarter ending Dec 31, 2026 is -$0.09 from 9 analysts, with estimates from -$0.18 to -$0.05.
How often does CDXS beat earnings estimates?
Codexis beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +25.02%.
CDXS pages: Overview, Earnings, Forecast, Financials, Competitors